Sequential Therapies After Osteoanabolic Treatment

Who May Qualify: • Postmenopausal women treated with severe osteoporosis completing their course with romosozumab or teriparatide Who Should NOT Join This Trial: - a bone disease other than postmenopausal osteoporosis - use of medications other than romosozumab or teriparatide affecting bone metabolism during the last 12 months before entering the study - creatinine clearance \<60 mL/min/1.73 m2 - liver failure - any type of cancer - uncontrolled endocrine diseases - serum 25-hydroxy vitamin D (25-OHD) concentrations lower than 20 ng/mL (50 nmol/L) - hypersensitivity to denosumab or zoledronate or teriparatide or romosozumab or any of the excipients Always talk to your doctor about whether this trial is right for you.